UNDER EMBARGO: Sunday May 31 7AM CST/ 8AM EST | In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC - Pharmaceutical Technology
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborations - Eli Lilly (NYSE:LLY)
A turning point for pancreatic cancer patients
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for…
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug…
